Hospira MitoXANTRONE Injection, USP (concentrate) 25 mg/12.5 mL vial

Χώρα: Αυστραλία

Γλώσσα: Αγγλικά

Πηγή: Department of Health (Therapeutic Goods Administration)

Δραστική ουσία:

mitoxantrone (mitozantrone) hydrochloride, Quantity: 2.33 mg/mL (Equivalent: mitoxantrone, Qty 2 mg/mL)

Διαθέσιμο από:

Hospira Australia Pty Ltd

INN (Διεθνής Όνομα):

mitoxantrone (mitozantrone) hydrochloride

Φαρμακοτεχνική μορφή:

Injection

Σύνθεση:

Excipient Ingredients: water for injections; sodium acetate trihydrate; glacial acetic acid; sodium chloride; sodium metabisulfite

Οδός χορήγησης:

Intravenous Infusion

Μονάδες σε πακέτο:

1 x 12.5 mL vial

Kατηγορία:

Medicine Listed (Export Only)

Τρόπος διάθεσης:

Not scheduled. Not considered by committee

Θεραπευτικές ενδείξεις:

Mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone in combination with other approved drus(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.

Περίληψη προϊόντος:

Visual Identification: A clear, dark blue solution; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store between 15-25 degrees Celsius

Καθεστώς αδειοδότησης:

Licence status A

Ημερομηνία της άδειας:

2007-08-20